doi:10.3390/jcm11020421engZabana, YamileMarín-Jiménez, IgnacioRodríguez-Lago, IagoVera, IsabelMartín-Arranz, María DoloresGuerra, IvánGisbert, Javier P.Mesonero, FranciscoBenítez, OlgaTaxonera, CarlosPonferrada-Díaz, ÁngelPiqueras, MartaLucendo, Alfredo J.Caballol, BertaMañosa, MíriamMartínez-Montiel, PilarBosca-Watts, MaiaGordillo, JordiBujanda, LuisManceñido, NoemíMartínez-Pérez, TeresaLópez, AliciaRodríguez-Gutiérrez, CristinaGarcía-López, SantiagoVega, PabloRivero, MontserratMelcarne, LuigiCalvo, MariaIborra, MarisaBarreiro de-Acosta, ManuelSicilia, BeatrizBarrio, JesúsPérez, José LázaroBusquets, DavidPérez-Martínez, IsabelNavarro-Llavat, MercèHernández, VicentArgüelles-Arias, FedericoRamírez Esteso, FernandoMeijide, SusanaRamos, LauraGomollón, FernandoMuñoz, FernandoSuris, Gerardde Zarate, Jone OrtizHuguet, José MaríaLlaó, JordinaGarcía-Sepulcre, Mariana FeSierra, MónicaDurà, MiguelEstrecha, SandraFuentes Coronel, AnaHinojosa, EstherOlivan, LorenzoIglesias, EvaGutiérrez, AnaVarela, PilarRull, NúriaGilabert, PauHernández-Camba, AlejandroBrotons, AliciaGinard, DanielSesé, EvaCarpio, DanielAceituno, MontserratCabriada, José LuisGonzález-Lama, YagoJiménez, LauraChaparro, MaríaLópez-San Román, AntonioAlba, CristinaPlaza-Santos, RocíoMena, RaquelTamarit-Sebastián, SonsolesRicart, ElenaCalafat, MargalidaOlivares, SonsolesNavarro, PabloBertoletti, FedericoAlonso-Galán, HoracioPajares, RamónOlcina, PabloManzano, PamelaDomènech, EugeniEsteve, MariaNationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA RegistryART-2022-131829We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.2022http://zaguan.unizar.es/record/12117710.3390/jcm11020421http://zaguan.unizar.es/record/121177oai:zaguan.unizar.es:121177info:eu-repo/grantAgreement/ES/ISCIII/COV20-00227Journal of Clinical Medicine 11, 2 (2022), 421 [20 pp.]byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess